MacroGenics, Inc.

MGNX13 Dec 2024
Healthcare
$3.35
0.00 (-0.29%)
Lowest Today
$3.27
Highest Today
$3.46
Today’s Open
$3.35
Prev. Close
$3.41
52 Week High
$21.88
52 Week Low
$2.95
To Invest in MacroGenics, Inc.

MacroGenics, Inc.

Healthcare
MGNX13 Dec 2024
0.00 (-0.29%)
1M
3M
6M
1Y
5Y
Low
$3.27
Day’s Range
High
$3.46
3.27
52 Week Low
$2.95
52-Week Range
52 Week High
$21.88
2.95
1 Day
-
1 Week
-3.41%
1 month return
-10.31%
3 month return
-8.37%
6 month return
-27.48%
1 Year return
-63.11%
3 Years return
-79.03%
5 Years return
-67.98%
10 Years return
-
Institutional Holdings
BB Biotech AG Ord
15.82
Bellevue Group AG
15.82
Armistice Capital, LLC
9.97
BlackRock Inc
8.61
Vanguard Group Inc
6.94
Millennium Management LLC
5.63
Wasatch Advisors LP
4.04

Market Status

Fundamentals
Market Cap
214.02 mln
PB Ratio
1.78
PE Ratio
0
Enterprise Value
47.76 mln
Total Assets
298.42 mln
Volume

Company Financials

Fund house & investment objective

Company Information
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Organisation
MacroGenics, Inc.
Employees
339
Industry
Biotechnology
CEO
Dr. Scott  Koenig M.D., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities